Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 6/20 | 0.37 |
| ▸ | DRD3 | P35462 | 6/20 | 0.37 |
| ▸ | DRD2 | P14416 | 6/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12820190 | 0.90 | HSD11B1 (0.42) | HSD11B1HTR2ADRD3DRD2KDM5A | |
| SCHEMBL12424261 | 0.86 | DRD3 (0.40) | HTR2ADRD3DRD2PKMKMT2A | |
| SCHEMBL25117891 | 0.81 | MTNR1A (0.45) | DRD2KMT2AEPHX2HPGDFASN | |
| SCHEMBL17200019 | 0.80 | HSD11B1 (0.46) | HSD11B1HTR2ADRD3DRD2PKM | |
| SCHEMBL12424436 | 0.80 | HSD11B1 (0.42) | HSD11B1HTR2ADRD3DRD2KDM5A | |
| SCHEMBL15014553 | 0.80 | HSD11B1 (0.42) | HSD11B1HTR2ADRD3DRD2KDM5A | |
| SCHEMBL15014487 | 0.76 | EPHX1 (0.47) | HSD11B1PKMKMT2AHPGDMEN1 | |
| SCHEMBL12424349 | 0.76 | KAT8 (0.35) | HTR2ADRD3DRD2PKMEPHX2 | |
| SCHEMBL22943926 | 0.75 | ATM (0.46) | DRD3DRD2KMT2AEPHX2FASN | |
| SCHEMBL26296778 | 0.75 | ATM (0.46) | DRD3DRD2KMT2AEPHX2FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | HSD11B1 291/4885HTR2A 3028/4885DRD3 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.